PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
Year: 2021
Type: conference-abstract
Source: Journal of Thoracic Oncology
Institutions: Chris O’Brien Lifehouse, Ankara Yıldırım Beyazıt University, Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Samsung Medical Center, Sungkyunkwan University, Asan Medical Center, Trakya University, Marmara University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Centre Hospitalier du Mans, Mahidol University, St Mary's Hospital Centre, University of Manchester, The Christie NHS Foundation Trust, China Medical University, China Medical University Hospital, China Medical University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Merck & Co., Inc., Rahway, NJ, USA (United States), German Center for Lung Research
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3137044741